
Tuesday, January 24, 2012
immatics presents positive Phase II results with its therapeutic cancer vaccine IMA910
Download : PR 240112
Tuesday, May 17, 2011
Pollen : "Notre produit permet un traitement à 5 injections"
Download : 24H 170511
Monday, March 28, 2011
Anergis closes CHF 18 million series A financing round to develop its innovative Allergy Vaccines and expands its Board of Directors
Download : Anergis PR 280311
Friday, September 24, 2010
Symetis reports on its trans-apical ACURATE TA™ first-in-man clinical study
Download : press release 230910
Tuesday, September 21, 2010
immatics raises €54 million to advance its late
stage clinical therapeutic cancer vaccine portfolio
Download : press release 21092010
Thursday, September 09, 2010
Sensimed AG receives International Recognitions: MD&DI 50 Companies to Watch, R&D100 and White Bull Finalist
Download : press release 080910
Thursday, September 09, 2010
Sensimed AG appoints Patrick Berdoz as Chairman of the Board of Directors
Download : press release 080910
Thursday, September 09, 2010
Sensimed AG extends oversubscribed Series B funding to CHF 18.6 Million
Download : press release 080910
Monday, September 06, 2010
The family business Schurter Retrofit AG has been sold.
Download : press release 060910
Thursday, June 24, 2010
Post-Vizepräsident leitet SolvAxis-Verwaltungsrat
Download : Bernerzeitung 230610
Friday, June 04, 2010
Une bonne PME, c'est aussi un bon conseil d'administration
Thursday, June 03, 2010
immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 for Glioblastoma.
Download : press release 020610
Tuesday, April 20, 2010
Sieben Fragen an Christian Waldvogel "Pensionskassen sind oft zu prozyklisch"
Download : NZZ 180410
Tuesday, February 16, 2010
immatics Enters Collaboration with Cancer Research UK to develop Multi-target Rationally Designed Therapeutic Cancer Vaccine
Download : 16feb10
Wednesday, February 03, 2010
SolvAxis accroît son capital pour réaliser ses ambitions
Download : Le Temps 030210
Vinci Capital - PSE-C - CH-1015 Lausanne - Tel +41 (0)21 693 92 34 - info@vincicapital.ch
Vinci Capital
PSE Bâtiment C
CH-1015 Lausanne
Tel +41 (0)21 693 92 34